Effects of furosemide and bendroflumethiazide on saliva flow rate and composition.
Aim of this study was to evaluate the effect on saliva flow rate and composition and on perceived xerostomia. The study used a Latin square design, all subjects being once daily (at 7.00 a.m.) taking the bendroflumethiazide (2.5 mg), furosemide (40 mg), or placebo, in a randomised order. Each treatment period of 7 days was separated by wash-out periods of 14 days. Unstimulated and paraffin chewing stimulated whole saliva, and 3% citric acid stimulated parotid and submandibular-sublingual secretion were collected twice daily, at 7.30 a.m., with the patients in a fasting condition (morning values), and at 10.30 a.m., about 2 h after intake of a standard breakfast (lunchtime values), on day 0 (baseline), day 1 (acute treatment), and day 7 (chronic treatment). Saliva flow rates were measured and all four secretions were analysed for the concentration of sodium, potassium, chloride, and total protein. Xerostomia was assessed by means of a Visual Analogue Scale. Statistical analysis used the Wilcoxon signed rank test. For flow rate, only that of submandibular-sublingual secretion was affected, significantly so in the morning during chronic treatment with both drugs. In resting whole saliva the output of both sodium and chloride tended to decrease especially during treatment with bendroflumethiazide, while in submandibular-sublingual secretion the output of all the electrolytes was decreased, especially for potassium and chloride and during treatment with furosemide. Further, xerostomia tended to increase during treatment with furosemide, statistically significant at lunchtime during chronic treatment. In conclusion, this study has demonstrated a modest effect on salivary flow rate and a more pronounced effect on saliva composition, especially in submandibular-sublingual secretion during treatment of healthy volunteers with therapeutic doses of two different diuretics, encouraging clinical studies in hypertensive patients and basic research as to the presence of a thiazide sensitive Na-Cl cotransporter in human salivary glands.
Nederfors
T
T
Department of Dentistry, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Nauntofte
B
B
Twetman
S
S
D000328:Adult; D001539:Bendroflumethiazide / Q000009:adverse effects*; D002712:Chlorides / Q000032:analysis; D004232:Diuretics / Q000009:adverse effects*; D005260:Female; D005665:Furosemide / Q000009:adverse effects*; D006801:Humans; D011188:Potassium / Q000032:analysis; D012463:Saliva / Q000737:chemistry / Q000187:drug effects*; D012471:Salivary Proteins and Peptides / Q000032:analysis; D012472:Salivation / Q000187:drug effects*; D012964:Sodium / Q000032:analysis; D014987:Xerostomia / Q000139:chemically induced
D002712:Chlorides; D004232:Diuretics; D012471:Salivary Proteins and Peptides; D001539:Bendroflumethiazide; D005665:Furosemide; D012964:Sodium; D011188:Potassium